However, as the combined treatment with IFN-α and tocilizumab induced higher DR4 expression compared with that of IFN-α treatment alone, it is suggested that IL-6-induced SOCS3 has, at least in part, a role in DR4 degradation in RCC cells. The gene discussed is IFNA1; the disease is renal cell carcinoma.